Pargyline Hydrochloride

Inquiry

Cat Number

API306070

CAS Number

306-07-0

If you have any other questions, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

306-07-0

EINECS

206-175-1

Storage

Store at -20℃

Synonyms

Benzylmethylpropynylaminehydrochloride;n-benzyl-n-methyl-2-propynylaminehydrochloride

Molecular Formula

C11H14ClN

Molecular Weight

195.69

Smiles

CN(CC#C)CC1=CC=CC=C1.Cl

Appearance

Powder

Melting Point

160-163℃

General Description

Pargyline Hydrochloride is a non-selective, irreversible monoamine oxidase (MAO) inhibitor used as an antihypertensive agent and investigated for antidepressant and neuroprotective effects. It blocks both MAO-A and MAO-B isoforms, preventing the oxidative deamination of endogenous and exogenous monoamine neurotransmitters, thereby increasing their synaptic concentrations.

Mechanism of Action

Pargyline Hydrochloride irreversibly inhibits monoamine oxidase A and B by forming a covalent adduct with the flavin adenine dinucleotide (FAD) cofactor at the active site of the enzyme. This leads to a sustained increase in synaptic levels of serotonin, norepinephrine, dopamine, and tyramine. The cheese reaction (hypertensive crisis triggered by tyramine-rich foods) is a notable consequence of non-selective MAO inhibition, resulting from excess tyramine displacing catecholamines from sympathetic nerve terminals.

Application

Pargyline Hydrochloride was indicated for the treatment of moderate to severe hypertension as a second- or third-line agent. It has also been investigated for potential neuroprotective effects in Parkinson's disease research.

A single dose of the monoamine oxidase (MAO) inhibitor Pargyline was administered either before or after ischemia-reperfusion (IR) in a rat model of kidney graft injury (uninephrectomy, IR, and daily cyclosporine for 28 days). Only pre-ischemia treatment significantly reduced interstitial fibrosis, tubular atrophy, necrosis, and apoptosis at day 28. This protection was associated with decreased expression of collagen I, III, IV, TGF-β1, MMP2, and inflammatory cytokines (IL-1β, TNF-α), along with normalization of antioxidant genes (SOD1, catalase) and reduced oxidative stress markers (8-OHdG, TBARS). Post-ischemia pargyline reduced inflammation but not fibrosis. MAO-A inhibition was transient. Blocking MAO-derived reactive oxygen species before reperfusion prevents long-term IFTA progression, suggesting that a single pre-treatment dose of pargyline could improve kidney transplant outcomes without the “cheese effect” risk of chronic MAO inhibitors.

Fig. 1 Effect of Pargyline treatment on fibrosis, tubular atrophy, necrosis and inflammation at 28 days post IR. (Chaaya R.; et al. 2011)

References

Chaaya R, et al. Pargyline reduces renal damage associated with ischaemia-reperfusion and cyclosporin. Nephrology Dialysis Transplantation, 2011, 26(2): 489-498.

What is the recommended storage condition for Pargyline Hydrochloride?

It should be stored at -20°C in a well-sealed container, protected from moisture and direct light, to maintain its chemical integrity throughout the shelf life.

Is a Certificate of Analysis (COA) available for Pargyline Hydrochloride?

Yes, a fully verified COA is issued for every batch and can be shared electronically. Additional documentation such as MSDS or impurity profiles may be requested separately.

What is the minimum order quantity (MOQ) for Pargyline Hydrochloride?

Flexible MOQ options are available to support both early-stage research and large-scale manufacturing needs. Our team can tailor order quantities to match your specific requirements.

Is Pargyline Hydrochloride available in multiple salt forms?

The standard commercial salt form is supplied; for inquiries about alternative salt forms or polymorphs, please contact our technical team.